Primary hypertension and diabetes mellitus
Conditions
Interventions
control group:treament of olmesartan for 8 weeks
experimental group:treament of sacubitril/valsarta for 8 weeks
Sponsors
Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients>=18 years old with mild to moderate primary hypertension, which is either untreated patients (either newly diagnosed or with a history of hypertension who had not received any antihypertensive drugs for >=4 weeks) with an office SBP>=145mm Hg and =145mm Hg and =4 weeks and HbA1c<7%.
Exclusion criteria
Exclusion criteria: Patients were excluded from the study if they receive any lipid lowering therapy or type 2 sodium-glucose cotransporter inhibitors. Other exclusion criteria include malignant or severe hypertension (office DBP >=110 mm Hg and/or office SBP >=180 mm Hg), secondary hypertension, history of angioedema, previous or current diagnosis of New York Heart Association class II to IV heart failure or clinically established atherosclerotic cardiovascular disease (ASCVD), or evidence of serious renal impairment (requiring dialysis or with estimated glomerular filtration rate 5.6mmol/L or LDL-C>3.4mmol/L).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| reduction of mean systolic blood pressure; | — |
Secondary
| Measure | Time frame |
|---|---|
| reduction of mean diastolic blood pressure;reducation of daytime mean systolic blood pressure/diastolic blood pressure;reducation of nighttime mean systolic blood pressure/diastolic blood pressure;blood pressure control (<130/80mm Hg); | — |
Countries
China
Contacts
Public ContactNaqiong Wu
Outcome results
None listed